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Pharmacological manipulation of L-carnitine transport into L6
cells with stable overexpression of human OCTN2
Abstract
The high-affinity Na+-dependent carnitine transporter OCTN2 (SLC22A5) has a high renal expression
and reabsorbs most filtered carnitine. To gain more insight into substrate specificity of OCTN2, we
overexpressed hOCTN2 in L6 cells and characterized the structural requirements of substances acting as
human OCTN2 (hOCTN2) inhibitors. A 1905-bp fragment containing the hOCTN2 complete coding
sequence was introduced into the pWpiresGFP vector, and L6 cells were stably transduced using a
lentiviral system. The transduced L6 cells revealed increased expression of hOCTN2 on the mRNA,
protein and functional levels. Structural requirements for hOCTN2 inhibition were predicted in silico
and investigated in vitro. Essential structural requirements for OCTN2 inhibition include a constantly
positively charged nitrogen atom and a carboxyl, nitrile or ester group connected by a 2-4-atom linker.
Our cell system is suitable for studying in vitro interactions with OCTN2, which can subsequently be
investigated in vivo.
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Abstract 
The high affinity Na+-dependent carnitine transporter OCTN2 (SLC22A5) has a 
high renal expression and reabsorbs most carnitine filtered. To gain more insight 
into substrate specificity of OCTN2, we overexpressed hOCTN2 in L6 cells and 
characterized the structural requirements of substances acting as hOCTN2 
inhibitors. A 1905 bp fragment containing the hOCTN2 complete coding 
sequence was introduced into the pWpiresGFP vector and L6 cells were stably 
transduced using a lentiviral system. The transduced L6 cells revealed increased 
expression of hOCTN2 on the mRNA, protein and functional level. Structural 
requirements for hOCTN2 inhibition were predicted in silico and investigated in 
vitro. Essential structural requirements for OCTN2 inhibition include a constantly 
positively charged nitrogen atom and a carboxyl, nitrile or ester group connected 
by a 2 to 4 atoms linker. Our cell system is suitable for studying in vitro 
interactions with OCTN2, which can subsequently be investigated in vivo. 
 
Key words: hOCTN2, secondary carnitine deficiency, drug-carnitine interactions; 
stable transfection; acylcarnitines; verapamil 
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Introduction 
Carnitine is essential for the transport of activated long chain fatty acids into the 
mitochondrial matrix of most cell types, where they can be metabolized by β-
oxidation [1; 2]. Beside its role in the transport of long-chain fatty acids, carnitine 
enables also the removal of potentially toxic short acyl-groups, e.g. acetate or 
propionate, from the mitochondrial matrix and/or cytosol [3; 4]. 
Loss of carnitine from the body is minimized by the Na+-dependent high affinity 
carnitine transporter OCTN2, which is primarily responsible for reabsorption of 
filtered carnitine in the kidney [5-8]. The importance of this carnitine transporter 
becomes apparent from the severe consequences of OCTN2-related disorders. 
In primary systemic carnitine deficiency (CDSP, OMIM 212140) [1; 4-9], caused 
by mutations in the SLC22A5 gene encoding for OCTN2, cellular (re)-uptake of 
carnitine is impaired [10-15]. Clinical findings in patients with primary carnitine 
deficiency result from low tissue carnitine levels and include myopathy, 
cardiomyopathy, hepatomegaly and failure to thrive [15-17]. Mutations in 
SLC22A5 (OCTN2) found more recently were associated also with peripheral 
neuropathy [18] and ventricular fibrillation [19]. 
Besides the well known roles of carnitine, several studies suggest that carnitine is 
involved in a multitude of other processes, for instance sperm quality assurance, 
immune responses or myocardial integrity and function, explaining the large 
interest for carnitine and OCTN2 [20-22]. 
Various drug interferences with carnitine transport [23-25] have been reported to 
cause secondary carnitine deficiency. Interference of various xenobiotics with 
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OCTN2 has been characterized by Ohasi et al. [26]. Cephalosporin antibiotics 
comprising a quaternary nitrogen have been shown to inhibit OCTN2-mediated 
carnitine reabsorption in the kidney [27]. Structural features in these compounds 
mimicking physico-chemical properties of carnitine may be responsible for 
inhibition of carnitine transport by OCTN2. Alternatively, allosteric interactions 
between xenobiotics and hOCTN2 may also be possible. Such drug-carnitine 
interactions may impair renal reabsorption of carnitine, possibly resulting in 
secondary carnitine deficiency. 
In the present study, the transport characteristics of carnitine into different cell 
lines were determined in order to identify a suitable cell line for overexpressing 
human OCTN2 (hOCTN2). Subsequently, a stably transfected cell line could be 
established, allowing the study of hOCTN2-driven carnitine transport. Some 
functional characteristics of this artificial hOCTN2 system were assessed and 
kinetic parameters of L-carnitine transport determined. Furthermore, this system 
enabled us to test the functionality of hOCTN2 in the presence of a variety of 
carnitine analogues as well as compounds comprising quaternary ammonium 
groups without structural similarity to carnitine and other compounds lacking 
structural similarities to carnitine. 
 
 
Materials and Methods 
Reagents 
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All chemicals were purchased from Sigma, except L-carnitine, which was 
obtained from Fluka (Buchs, Switzerland). L-[3H]-carnitine hydrochloride (81 
Ci/mmol) was obtained from Amersham-Pharmacia Biotech (Little Chalfont, 
Buckinghamshire, England). Trimethylhydraziniumpropionate was synthesized as 
described previously [28]. 
 
Cell culture 
L6 cells (rat skeletal muscle myoblasts, obtained from American Type Culture 
Collection, Rockville, USA) and EBNA cells (human primary embryonal kidney, 
also from American Type Culture Collection) were grown in Dulbecco’s modified 
Eagle’s medium (DMEM), supplemented with 10% fetal bovine serum (FBS), 1 
mM sodium pyruvate and 100 U/mL penicillin and 100 µg/mL streptomycin (all 
substances from Invitrogen, Switzerland) at 37°C with 5% CO2 and 95% 
humidity. 
For green monkey kidney cells (COS7 cell line) the above described medium was 
supplemented with 10 mM Hepes. 
 
Preparation of polyclonal antibodies against OCTN2 
The polyclonal antibody anti-OCTN2/K33 was generated to recognize a C-
terminus amino acid sequence of the rat OCTN2 (amino acids 543-557). The 
peptide was coupled at the N-terminus to keyhole limpet hemocyanin (KLH) to 
increase its immunogenicity. The structure of the construct was as follows: 
KLH-Tyr-Lys-Asp-Gly-Gly-Glu-Ser-Pro-Thr-Val-Leu-Lys-Ser-Thr-Ala-Phe-COOH 
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Rabbits were immunized and serum obtained as described previously [29]. 
 
Characterization of the antibodies 
The antibodies were characterized by Western blotting of human and rat tissues, 
peptide competition and in situ hybridization in rat tissue. Male Sprague Dawley 
rats (150-200 g) housed under standard conditions were sacrificed by 
decapitation, tissues were excised and immediately frozen in liquid nitrogen. 
Human tissues were obtained from cadavers <20 hours post mortem (Institute of 
Pathology, University Hospital Basel). 
For Western blotting, tissues were homogenized at a concentration of 1g/6mL 
with a polytron homogenizer (Kinematica, Switzerland) in cold homogenization 
buffer (20mM TrisHCl pH6.8, 1% SDS, 1mM DTT, containing Complete Mini® 
antiprotease cocktail (Roche, Switzerland)) and centrifuged (700g, 5min) at 4°C. 
Homogenate (50 μg protein) was combined with the same volume of loading 
buffer (2% SDS, 10% glycerol, 100mM TrisHCl pH 6.8, bromophenol blue, 5mM 
DTT), heated to 50°C for 3min and loaded onto a 10% SDS-polyacrylamide gel. 
Proteins were separated in Tris-Glycine running buffer (25mM Tris, 192mM 
glycine, 0.1% SDS, pH8.3) and transferred to nitrocellulose filters (Hybond ECL, 
APBiotech, Piscataway, USA) using a wet-transfer cell (Bio Rad, Reinach, 
Switzerland) in a buffer containing 25mM Tris, 192mM glycine, pH8.3, and 10% 
methanol (1 hour, 400mA). The filter was blocked in 3% defatted milk powder in 
PBS and exposed to the primary antibody anti-OCTN2/K33 antiserum (1:1000) in 
PBS/milk for 2 h. Secondary HRP conjugated antibody to rabbit IgG (APBiotech, 
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Piscataway, USA) was used 1:5000 for 30-45min in PBS/milk and the blot was 
rinsed 4 times in PBS/milk and twice in PBS. Antibody binding was visualised 
with an ECL detection system (APBiotech, Piscataway, USA). 
For peptide competition experiments, anti-OCTN2/K33 rabbit serum was 
preincubated with an excess of either the specific immunogen or a similar non 
specific peptide. Briefly, 2μl of rabbit sera (30μg or 200pmoles IgG) was pre-
adsorbed with 50μg (30nmoles) of the non-specific antigen K34/OCTN2 (KLH-
Tyr-Leu-Pro-Asp-Thr-Ile-Asp-Gln-Met-Leu-Arg-Val-Lys-Gly-Ile-Lys-COOH) or 
specific antigen (K33/OCTN2) at room temperature in 500μl PBS for 2 h. Two 
nitrocellulose filters were prepared containing electrophoresed samples (25-
50μg) of a rat kidney heavy and a rat kidney light membrane fraction (see below). 
After 2 h, the volume of the antigen-antibody solution was made up to 4ml in PBS 
3% milk (1:2000 dilution of sera) and applied separately to one of the 
nitrocellulose filters. The filters were incubated for 2 h room temperature with 
either one of the pre-adsorbed antisera, washed and detection continued as per 
normal Western blotting procedure. 
For the preparation of the membrane fractions, 1 g rat kidney was cut frozen (-
70°C), minced with scissors and homogenized with a polytron in 6ml of ice-cold 
homogenization buffer (0.25M sucrose, 10mM TrisHCl pH8, antiprotease cocktail 
Roche). The resulting homogenate was centrifuged at 800g 4°C for 5 min and 
the supernatant centrifuged at 10,000g 4°C 15min. The supernatant was then 
subjected to a 150,000g spin for 1h in a Beckman ultracentrifuge (SW55Ti rotor, 
Beckman, Nyon, Switzerland) and the resulting pellet was resuspended in 1ml 
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homogenization buffer containing 8% (w/v) sucrose and loaded onto a sucrose 
gradient (20/30/40/50/70% w/v sucrose in Tris buffer, pH8). The gradient was 
spun for 18 h at 80,000g in a swing out rotor (SW28 rotor, Beckman) and the 
visible protein fractions at the 40/50% (fraction 4 = heavy fraction) and at the 
20/30% interface (fraction 6 = light fraction) were collected, diluted in Tris buffer 
pH8 (no sucrose) and pelleted at 100,000g for 1 h. The pellets were resuspended 
in 100-1000ul of homogenization buffer and the protein concentration assayed 
(Biorad protein assay reagent using bovine serum albumin as a standard). The 
heavy membrane fraction gave a strong signal with antibodies against Na+/K+ 
ATPase and aminopeptidaseN, indicating a high brush border membrane content 
(data not shown). In the lighter membrane fraction, these signals were less 
pronounced (not shown). 
For in situ hybridization experiments, rat and human tissues were collected 
freshly, cut into 2-3mm cubes, and placed into 4% paraformaldehyde in PBS for 
3-16 h at 4°C with gentle shaking for fixation. Tissues were rinsed in multiple 
changes of PBS and stored in 25% PVP-10 sucrose in PBS, 4°C overnight. 
Tissues were mounted on silan coated slides and sections blocked prior to 
labeling with a 1:20 solution of goat serum in PBS/BSA blocking solution. 
Immunolabelling was performed at room temperature and antibodies diluted in 
wash solution (PBS + 0.5% BSA). Primary antibody was anti-OCTN2/K33 1:200 
and secondary antibody was Cy2 labeled goat anti-rabbit 1:300. Wash steps 
were for 15min with 4-5 changes of buffer, primary antibody was allowed to bind 
for 1h and the secondary for 30-45min insulated from light. The labeled 
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coverslips were mounted onto glass slides and allowed to set before visualizing. 
The slides were viewed using a Zeiss axiophot fluorescent microscope and 
images taken with analySIS software (Zeiss Instruments, Heerbrugg, 
Switzerland). 
 
Production of lentiviral vectors and transduction of L6 cells. 
A 1905 bp fragment containing the hOCTN2 complete coding sequence was 
isolated from EBNA cells and introduced into the pWpiresGFP vector (kind gift of 
Dr. Didier Trono, University of Geneva). The new recombinant plasmid was 
verified on mutations by DNA sequencing. Lentiviral vector envelope plasmid 
pMD2.G and packaging plasmid pCMC∆R8.91 were kindly provided by Dr. Didier 
Trono (University of Geneva). For the production of HIV-derived vectors, the 
envelope plasmid pMD2.G, the packaging plasmid pCMC∆R8.91 and the vector 
plasmid pwPhOCTN2iresGFP (or empty vector pwPiresGFP) were introduced 
into 293T cells by calcium phosphate precipitation as described by 
Salmon/Molecular Therapy 2/4/2000). After 12 hours the medium was replaced. 
The supernatant was harvested 38 hours post transfection, centrifuged at 2500 
rpm, filtered through a 0.45 µM filter and stored at 4°C. Fresh medium was added 
to the cells and after 24 hours, the harvest procedure repeated. The viral stocks 
were pooled, aliquoted and stored at –70°C. 
 
Expression of hOCTN2 in L6 cells 
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L6 cells, grown to about 50% confluency in 6-well plates, were incubated with 
virus supernatant prepared as detailed in the preceding section in the presence 
of Polybrene® (Aldrich, Buchs, Switzerland). Success of transduction was 
estimated with fluorescence activated cell sorting (FACS) analysis. Enhanced 
green fluorescent protein (EGFP)-positive-cells were enriched by FACS and cell 
culture was continued with this population. 
Expression of hOCTN2 in the transduced L6 cells was determined with 
quantitative real time PCR. Total RNA was isolated with Rneasy® (Qiagen Basel, 
Switzerland) as described by the manufacturer. Superscript TM II together with 
Oligo (dT) and Random Hexamer primers (Gibco BRL, Basel, Switzerland) was 
used for reverse transcription of 2 µg total RNA. Quantification was performed on 
a ABI PRISM 7700 Sequence Detector (PE Biosystems, Rotkreuz, Switzerland). 
Reporter probes hOCTN2 and GAPDH FAM/TAMRA were from Eurogentec 
(Seraing, Belgium), the hOCTN2 and GAPDH forward and reverse primers were 
from Microsynth (Balgach, Switzerland). PCR conditions were 95°C for 10 
minutes, preceded by a 2 minutes step at 50°C, and 40 cycles 95°C for 10 sec, 
60°C for 60 seconds. The total reaction volume was 25 µl. For each cell type, a 
serial dilution of DNA was used (range: 6.25 - 50 ng) to investigate whether the 
CT method could be used for calculation. GAPDH primers and probe were: 
forward primer 5’-GGTGAAGGTCGGAGTCAACG-3’ and reverse primer: 5’-
ACCATGTAGTTGAGGTCAATGAAGG-3’ and the probe 5’-
CGCCTGGTCACCAGGGCTGC-3’. The primers for the carnitine transporter 
hOCTN2 were designed to amplify a region that is highly conserved between 
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human and rodent species. The forward primer was 5’-C(A or 
C)TATGTGTTGGCCTGGCTG-3’, the reverse primer 5’- 
AACTTGCCCACCATCACCAG-3’ and the probe 5’-
CTCTTCCTGGGTGGCAGTGTCCTTCTCT-3’. 
 
Flow cytometry analysis and immunohistochemistry of L6 cells overexpressing 
hOCTN2 
For immunohistochemistry, cells were grown for 24 hours at 37°C in an 8-
chamber slide coated with poly-D-lysine. After washing, cells were visualized by 
phase contrast microscopy and, after incubation with anti-OCTN2 (1:200, 30 min) 
and/or fluorescent labelled Cy3 sheep anti-rabbit Ig (1:300, 20 min), by 
fluorescence microscopy (Olympus IX 50, Hamburg, Germany). 
For flow cytometry, cells were rinsed with PBS and harvested with 10 mM EDTA. 
The detached cells were pelleted, resuspended in PBS supplemented with 2% 
FBS, and passed through a filter (40 µM) to obtain single cells. Cells were fixed 
with 2% paraformaldehyde for 20 minutes, washed and incubated with anti-
OCTN2 antiserum anti-OCTN2/K33 (1/200 dilution) for 30 minutes. Cells were 
washed again before adding the fluorescent labelled Cy3 sheep anti-rabbit Ig 
(Sigma) for 20 minutes. 2x104 cells were used for analytical cell sorting on a 
FACSCalibur analyzer (Becton-Dickinson, Allschwil, Switzerland). 
 
Functional characterization of L6 cells overexpressing hOCTN2 
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The functionality of the hOCTN2 construct was evaluated by L-[3H]-carnitine 
transport measured at 30°C. Cells were grown to confluency on 12-well plates 
(Becton-Dickinson, Allschwil, Switzerland), washed two times with and then 
incubated for 5 minutes in 2 ml of prewarmed sodium uptake buffer (116 mM 
NaCl, 5.3 mM KCl, 0.8 mM MgSO4, 26.2 mM NaHCO3, 1 mM NaH2PO4 , 5.5 mM 
D-glucose, pH=7.4). The total uptake of L-[3H]-carnitine was determined by 
incubating the cells with 0.5 ml of sodium uptake buffer containing 50 µM L-
carnitine (5 µCi/0.5 ml) for 8 minutes at 30°C. The uptake was stopped by the 
addition of 2 ml of ice cold choline wash buffer (116 mM choline chloride, 5.3 mM 
KCl, 0.8 mM MgSO4, 26.2 mM choline bicarbonate, 1 mM KH2PO4 , 5.5 mM D-
glucose and 1 mM L-carnitine, pH=7.4). After washing the cells twice with 2 ml 
ice cold choline uptake buffer, they were solubilized with 1 ml of 1% SDS (w/v). 
After addition of 5 ml scintillation fluid (Ultima-goldTM, Packard Bioscience, Zürich, 
Switzerland), the cell associated radioactivity was counted. 
For the sodium independent L-carnitine uptake, the sodium uptake buffer was 
replaced by choline uptake buffer (does not contain L-carnitine, but is otherwise 
identical with the choline wash buffer). Otherwise the same procedure was 
applied. 
The sodium-dependent L-carnitine uptake was obtained as the difference 
between total L-carnitine uptake (L-carnitine uptake determined in the presence 
of the sodium uptake buffer) and sodium-independent L-carnitine uptake. 
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In experiments dealing with inhibition of transport, cells were preincubated for 15 
minutes with 0.1 and 1.0 mM (or 0.05 and 0.5 mM) inhibitor candidates before 
starting the uptake experiments executed as described above. 
The protein concentration was determined using the BCA assay (Pierce, 
Rockford, IL, USA. 
 
Search for compounds mimicking carnitine 
At first, known substrates of OCTN2 that interfere with the transport of L-carnitine 
were analyzed in order to identify common structural features that might be 
responsible for this behavior. Superposition of an energy minimized 3D-structure 
of L-carnitine on a X-ray structure of cephaloridine revealed a good match of the 
positively charged tetramethylammonium group and the carboxylate group of L-
carnitine with the charged pyridinium nitrogen and the carboxylate groups in the 
antibiotic, respectively (Fig. 1A). The 3D-structure of cephaloridine was obtained 
from the Cambridge Structural Database (CSD) [30]. It was tempting to assume a 
functional role for both the negatively ionizable carboxylate and the constantly 
positively charged ammonium groups and thereby identifying critical 
pharmacophores in the interaction of L-carnitine with OCTN2 (Fig 1B). 
Subsequently, the Merck index [31] was searched for compounds comprising 
such a pharmacophore pattern with more or less constraints for the distance 
between the negative and positive charges (linker of 2 to 6 saturated C-C bonds). 
Further compounds were identified in the “Index Nominum 2000” 
(http://www.micromedex.com/products/indexnominum/). Selected substances 
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were divided into four groups (Fig 1C): 1. Molecules comprising an ammonium 
ion connected to a carboxylic acid with a 3 to 5 atoms linker, 2. Molecules 
comprising ammonium ions and derivatives thereof but not bearing a carboxylic 
acid group 3. Molecules comprising a positively charged nitrogen in a 
heteroaromate with or without a carboxylic acid group, and 4. cephalosporins or 
other compounds lacking a permanently positive charge (Figure 1C). 
Selected substances were then tested for their inhibitory effect on L-carnitine 
transport using L6 cells overexpressing hOCTN2. The transport activity of L-
carnitine was determined as described before. 
 
Possible interactions between cefalotin and L-carnitine 
Possible interactions between cefalotin and L-carnitine were studied by 
assessing the effect of L-carnitine on the absorption spectrum of cefalotin and by 
assessing the effect of cefalotin on the L-carnitine concentration during the L-
carnitine transport experiments. 
For studying the effect of L-carnitine on the absorption spectrum of cefalotin, 
cefalotin was dissolved at two concentrations (100 and 1000 μmol/L, 
respectively) in sodium uptake buffer (116 mM NaCl, 5.3 mM KCl, 0.8 mM 
MgSO4, 26.2 mM NaHCO3, 1 mM NaH2PO4 , 5.5 mM D-glucose, pH=7.4) and the 
absorption spectrum was obtained between 190 and 600 nm. After the addition of 
100 μmol/L L-carnitine, the same absorption spectrum was obtained and the 
spectra were compared. 
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To investigate a possible effect of cefalotin on the degradation of L-carnitine, L6 
cells overexpressing hOCTN2 were incubated in sodium uptake buffer (see 
above) containing different cefalotin concentrations (0, 100 or 1000 μmol/L) at 
30°C. After the addition of L-carnitine (25 or 50 μmol/L), L-carnitine transport was 
allowed to proceed for 8 minutes. After 8 minutes, the reactions were stopped by 
centrifugation of the suspensions (10’000 x g at 5°C for 1 minute). The 
concentrations of free and total acid soluble carnitine were measured in the 
supernatant as described by Brass and Hoppel [32]. 
 
Kinetic analysis of carnitine transport 
The kinetic parameters of L-carnitine transport into L6 cells transfected with 
hOCTN2 were calculated using the program sigmaplot version 10 (Scientific 
Solutions, www.scientific-solutions.ch). After subtraction of the values obtained in 
the presence of choline from those in the presence of sodium, data were fitted 
using nonlinear least squares regression analysis to: 
SK
SVv
m
max
+
×=  
where v and S are the uptake rate and the concentration of L-carnitine, 
respectively, Vmax is the maximal transport rate for L-carnitine and Km the 
Michaelis-Menten constant. 
For the determination of the IC50 value for verapamil, the data were fitted to: 
Hillslope
50 )IC/x(1
minmaxActivity +
−=  
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using sigmaplot version 10. Max is maximal activity (inhibitor concentration zero), 
min is the minimal activity, x is the concentration of the inhibitor, IC50 the 
concentration of the inhibitor at 50% inhibition of the activity and Hillslope the 
slope of the curve. 
 
 
Results 
Production and characterization of antibodies against OCTN2 
One of two rabbits immunized developed antibodies against a protein at 67kD on 
the Western blot of rat kidney and rat kidney brush border membrane vesicles 
(data not shown). Further characterization of the antiserum (anti-OCTN2/K33) 
obtained from this rabbit showed that it also reacted with human kidney tissue 
(on Western blots) obtained post mortem (data not shown). 
In order to demonstrate the specificity of the anti-OCTN2/K33 serum, a 
competition experiment with the peptide used for immunization was performed. 
As shown in panel "a" of Figure 2A, K33 pre-treated with an unspecific peptide 
identifies a 67 kD protein in the k4 fraction of rat kidney. This band (indicated by 
an arrow) can also be detected in the k6 fraction, but is much fainter. After pre-
treatment of anti-OCTN2/K33 with the peptide used for antibody production, both 
bands at 67 kD have vanished (panel b of Figure 2A). Finally, as shown in Figure 
2B, immunohistochemistry of rat kidney sections showed the expected 
localization of OCTN2 on the luminal side of proximal tubules. Similar results 
were obtained with human kidney (results not shown). 
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Characterization of hOCTN2 expression in stably transduced L6 cells 
FACS analysis revealed a primary success rate of transduction of approximately 
60% in L6 cells. Cells were cultured and characterized first by mRNA expression 
of hOCTN2 using RT-PCR. Quantitative real time PCR showed a >250-fold 
increase of hOCTN2 mRNA expression in L6 transfected cells as compared to 
mock transfected L6 cells (not shown). The presence of the hOCTN2 transporter 
was further demonstrated by immunohistochemistry (Figure 3A) and by FACS 
analysis (flow cytometry analysis, Figure 3B). 
The functionality of the hOCTN2 construct in L6 cells was evaluated by L-[3H]-
carnitine uptake experiments, where, for assessing the sodium-independent 
uptake, Na+ was replaced by choline in the transport buffer. We found the Na+-
dependent L-[3H]-carnitine uptake to be approximately 25-fold higher in hOCTN2 
transduced L6 cells as compared to mock transfected L6 cells after 8 minutes of 
exposure at 30°C (Figure 4A). In contrast, the Na+-independent transport activity 
remained unchanged in transduced L6 cells as compared to the mock 
transfected L6 cells. The uptake was linear for at least 8 minutes. 
Next, the concentration dependency of the L-carnitine transport was determined 
and kinetic parameters were calculated. As shown in Figure 4B, the transport of 
L-carnitine was saturable after correction for a non-saturable component. The 
calculated Km and Vmax values for L-[3H]-carnitine transport are 9.7±0.3 μM and 
290±4 pmol/mg protein/min, respectively. 
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Inhibitors of carnitine transport by hOCTN2 
Four groups of compounds were selected as described in Material and Methods 
and subsequently tested for their capacity to interfere with L-carnitine transport 
by hOCTN2. Derivatives of L-carnitine and close structural analogs (group 1, e.g. 
acylcarnitines, butyrobetaine and trimethylhydraziniumpropionate, demonstrated 
a strong inhibition of the L-carnitine uptake by transfected L6 cells (Table 1). The 
nature of the atoms linking the charged group is not of critical importance for 
recognition by hOCTN2 (compare L-carnitine vs. 
trimethylhydraziniumpropionate). However, a linker length of at least three atoms 
between ammonium ion and carboxylate is crucial for recognition by the 
transporter as is clearly indicated by the lack of interaction for betaine that 
comprises only a short linker. Substituents of different length connected to the 
linker are tolerated by hOCTN2 without loss of inhibition, unless the substituent is 
branched. (Table 1, compare hexanoylcarnitine vs valproylcarnitine, 
pivaloylcarnitine). Interestingly, removal of a single methyl group and thereby the 
constant charge from the ammonium functionality results in complete loss of 
inhibitory power (Table 1, compare butyrobetaine vs. dimethylaminobutyric acid). 
Replacement of the negatively charged carboxylate by an ester or inverted ester 
group did not decrease the inhibitory activity, as long as the linker consisted of at 
least 3 atoms (Table 2, e.g. atropine methylbromide, anisotropine methylbromide, 
ipratropium bromide). Apparently, the inactive scopolamine butylbromide seems 
to disobey this rule, however, this lack of interaction with hOCTN2 may be a 
consequence of the extended alkyl group attached to the ammonium ion (Table 
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2, compare scopolamine methylbromide vs. scopolamine butylbromide). 
Neostigmin bromide showed no inhibitory activity, either due to the exchange of 
the ester to a carbamate group or due to its very rigid geometry that could 
prevent productive interaction with the protein. Shortening the distance between 
ammonium ion and inverted ester or removing the ester function resulted in loss 
of the inhibitory activity (Table 2, see acetylcholine, carbamylcholine, 
decamethonium bromide). 
Incorporation of the positive charge into a heteroaromate resulted in a substantial 
or complete loss of the inhibitory activity (Table 3). Interestingly, of the two 
cephalosporins comprising a constant positive charge only cefozopran showed a 
weak inhibitory activity, while ceftazidime did not interfere with L-carnitine 
transport at all, despite the presence of a three-atom linker between the charged 
pyridinium nitrogen and carboxylate. Pancuronium bromide displayed an 
unexpected weak inhibitory activity, despite comprising only a short two-atom 
linker between ammonium ion and inverted ester. Not surprisingly, pyridostigmine 
bromide comprising only a short linker as well as amprolium hydrochloride and 
hexadecylpyridinium bromide, which both lack the carboxylic acid functionality, 
were completely inactive. 
All substances lacking the constantly ionized nitrogen were completely inactive 
up to this point (see Table 4 and dimethylaminobutyric acid in Table 1). One 
substance not following this rule was cefalotin, which appeared to stimulate 
transport of L-carnitine by OCTN2. In order to study the possible formation of a 
complex between cefalotin and L-carnitine, the absorption spectrum of cefalotin 
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(100 or 1000 μmol/L) was obtained in the absence and presence of 100 μmol/L 
L-carnitine. Since the addition of L-carnitine did not change the absorption 
spectrum of cefalotin (data not shown), the formation of a complex between the 
two compounds could be excluded under the conditions used. Furthermore, a 
possible inhibition of L-carnitine degradation by cefalotin was studied in 
incubations containing different L-carnitine (25 or 50 μmol/L) and cefalotin 
concentrations (0, 100, 1000 μmol/L). The results showed that L-carnitine is not 
degraded under the conditions studied and that cefalotin has no effect on L-
carnitine degradation (data not shown), excluding this possibility as a reason for 
the observed increase in carnitine transport in the presence of cefalotin. 
Another molecule behaving against the rule that a positive charge is required for 
interference with L-carnitine transport by OCTN2 was verapamil. In agreement 
with a previous report [33], verapamil hydrochloride was found to be a strong 
inhibitor of hOCTN2 (Fig 1C). In order to further characterize this inhibitory effect 
exerted by verapamil, the IC50 was determined to be 5.3 μM (Figure 5). In this 
context, the complete lack of inhibitory activity of dimethylaminobutyric acid is 
remarkable, considering its close topological relationship with the highly active 
butyrobetaine. In general, a permanent positive charge appears to be crucial for 
a compound interfering with L-carnitine transport by hOCTN2. 
 
 
Discussion 
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The membrane protein OCTN2 is a member of the sodium-dependent organic 
cation transporters, with a high affinity for L-carnitine. In humans, OCTN2 is 
expressed strongly in kidney but only weakly in skeletal muscle, liver, lung, brain 
and small intestine [6], whereas the rat counterpart is highly expressed in kidney 
and testis, but to a lesser extent in liver and small intestine [28; 34]. 
The substrate specificity of OCTN2 is broad, as several other cations, in 
particular carnitine derivatives and carnitine analogues are able to compete with 
and inhibit L-carnitine transport [7]. We therefore established and characterized a 
heterologous expression system designed for measuring transport inhibition of L-
carnitine by compounds with more or less structural similarity. The strong 
inhibition exhibited by some of these selected compounds (Table 1) is consistent 
with reports found in the literature [7; 26; 35; 36]. Surprisingly, also therapeutics 
do interfere with OCTN2-mediated L-carnitine transport [33], among them some 
members of the cephalosporin family as reported by Ganapathy et al. [27]. 
The interaction of certain cephalosporins with the OCTN2 transporter can most 
likely be attributed to the presence of a pharmacophore pattern (Fig. 1B) in the 
substances that mimic L-carnitine. As a working hypothesis, we assumed the 
pharmacophore pattern to consist of a quaternary nitrogen that is separated by 
three atoms from a carboxylic acid functionality, thereby mimicking the topology 
of L-carnitine. In order to test this hypothesis and to explore its rigidity, we 
selected compounds and divided them into four categories of as described in the 
results section. 
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Carnitine and close derivatives thereof (Table1) have all a very profound 
inhibiting effect on L-carnitine transport by hOCTN2. A linker of three atoms 
between the two functionalities (ammonium ion, carboxylic acid) appears to be 
critical as exemplified by the short-linked betaine being completely inactive. 
Substitutions at the linker are neither required nor forbidden and therefore without 
importance, as evidenced for butyrobetaine and trimethylhydraziniumpropionate. 
Even long substituents such as palmitoyl are well tolerated as long as they are 
unbranched. The slightly decreased inhibitory activities of the branched linker 
substituents contained in valproyl- and pivaloylcarnitine (Table1) might indicate a 
spatial restriction executed by hOCTN2 in the linker region. 
The ammonium ion is crucial for recognition as can be seen from the complete 
inactivity of dimethylaminobutyric acid. In order to further evaluate the individual 
requirements of the two linked functional groups, a second set of compounds, 
either comprising a derivatized neutral carboxylic acid functionality or no such 
functionality, was selected (Table 2). If the ammonium functionality comprises at 
least two methyl substituents, an inverted ester separated by two atoms is well 
tolerated and even a branched isopropyl substituent (ipratropium bromide) or a 
bridge between two substituents (pancuronium bromide) of the charged nitrogen 
is still accepted by hOCTN2. Surprisingly, in scopolamine derivatives, there is a 
striking difference between the very well recognized N-methyl compound and the 
more voluminous, but almost inactive, N-butyl derivative. A search through the 
PDB database [37] revealed a high preference for electron rich aromatic side 
chains like tyrosine or tryptophane enclosing an ammonium functionality. Lengthy 
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and more voluminous substituents like the N-butyl group might adversely 
interfere with a close contact between amino acid side chains and the ammonium 
functionality and therefore hamper the recognition of scopolamine N-butyl 
bromide. A shortened two atom linker between the ammonium functionality and 
an inverted ester is not tolerated in rather small molecules (Table 2, acetyl 
choline) and likewise introduction of a carbamate functionality is absolutely 
detrimental for recognition by hOCTN2 (Table 2, carbamylcholine, neostigmine). 
Absence of a carboxylic acid functionality also leads to non-recognition by the 
transporter (Table 2, decamethonium bromide).  
A constant positive charge can not only reside in an ammonium ion but also in a 
heteroaromate as e.g. in cephaloridine that has been shown to interfere with L-
carnitine transport by hOCTN2 [27]. In order to further asses the capability of 
hOCTN2 to transport various positively charged heteroaromates, we selected 
compounds comprising such an entity but lacking further constantly positive 
charged functionalities (group 3). The two charged cephalosporine derivatives 
showed either no (Table 3, ceftazidime) or only borderline activity (cefozoprane), 
despite the presence of a charged carboxylate group separated by a three atom 
linker (ceftazidime). Of the other selected examples (Table 3) none showed 
significant activity which could be indicating a steric handicap of the disc-shaped 
heteroaromates that can not be properly recognized by the "active site" in 
hOCTN2. 
Since cephaloridine is a known inhibitor of L-carnitine transport by hOCTN2 [27], 
it was more than tempting to check whether the cephalosporin scaffold per se 
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without bearing a constant charge is recognized by the transporter. This question 
can be clearly negated since none of the eight tested cephalosporine or penicillin 
derivatives showed significant interference with the L-carnitine transport (Table 
4). After exclusion of direct interactions between cefalotin and carnitine, the most 
likely reason for the observed stimulation of carnitine transport by cefalotin is an 
allosteric interaction with OCTN2, an assumption needing more detailed studies 
to be proven. So far, no other compounds with such properties have been 
described. 
Not obeying the rules mentioned so far, verapamil (Fig 1C) was identified as a 
strong inhibitor of hOCTN2 (Table 4 and Figure 5). This molecule comprises 
neither a constantly charged nitrogen ion nor a carboxylic acid derivative 
separated by a three atom linker. The inhibitory effect of verapamil on carnitine 
transport has been described in an oocyte system with hOCTN2 expression [33] 
and in heart and skeletal muscle explants [38], but the mechanisms of inhibition 
are so far not clear. It cannot be completely excluded that the tertiary nitrogen, in 
combination with the nitrile group, could be mimicking a pair of pharmacophores 
that are strongly recognized by hOCTN2. As an alternative, verapamil might be 
acting via an allosteric inhibitor and thereby not directly interfere with L-carnitine 
recognition and transport by hOCTN2. 
Further studies will therefore be necessary to understand the relationship 
between structure and inhibitory or stimulatory capacity of drugs and chemicals 
towards hOCTN2. Since inhibition of hOCTN2 by chemical compounds can be 
associated with systemic carnitine deficiency [27; 33], identification of hOCTN2 
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inhibitors appears to be clinically important. Our model provides the basis for 
identification and rapid screening of possibly interacting substances, but the 
clinical relevance of hOCTN2 inhibition observed in vitro needs to be studied in 
animals or humans in vivo. It has also to be taken into account that inhibition of 
hOCTN2 is not the only mechanism associated with secondary carnitine 
deficiency [26; 33]. 
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Figure legends 
 
Figure 1 
Characterization of the substances used as potential inhibitors of hOCTN2. A: 
Superposition of L-carnitine (blue) on cephaloridine (green), showing the 
structural similarity. B: L-carnitine (blue) with the two pharmacophores 
postulated: the ammonium functionality (red ball) and the carboxyl group (green 
ball). C: The substances selected based structural similarity with L-carnitine and 
tested for inhibition of L-carnitine transport were 1. substances containing an 
ammonium ion connected to a carboxylic acid with a 3 to 5 atoms linker, 2. 
ammonium ions and derivatives thereof not linked to a carboxylic acid group, 3. 
substances comprising a positively charged nitrogen in a heteroaromate with or 
without a carboxylic acid group, and 4. substances lacking a constantly positive 
charge (e.g. cephalosporins, verapamil). Typical representatives of each group 
are shown. 
 
Figure 2 
Characterization of the antiserum against a polypeptide of the preterminal region 
of rat OCTN2 (anti-OCTN2/K33). A: Anti-OCTN2 serum treated with an 
unspecific peptide identifies a 67 kD protein in the k4 (heavy membrane fraction) 
and, fainter, in the k6 fraction (light membrane fraction) of rat kidney (panel a). 
After pre-treatment of anti-OCTN2 serum with the peptide used for antibody 
production, both bands at 67 kD have vanished (panel b). B: 
Immunohistochemistry of rat kidney sections shows the expected localization of 
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OCTN2 on the luminal side of proximal tubular cells in sections treated with anti-
OCTN2 serum (primary antibody) and Cy2 labeled goat anti-rabbit (secondary 
antibody) (panel b). In sections treated with secondary antibody only, the 
fluorescence pattern is unspecific (panel a). 
 
Figure 3 
Morphological characterization of the L6 cells transfected with hOCTN2. A: Cells 
were grown in an 8-chamber slide, washed and visualized by phase contrast 
microscopy (panel a). Other slides were incubated with anti-OCTN2 (1:200, 30 
min) and/or fluorescent labelled Cy3 sheep anti-rabbit Ig (1:300, 20 min) and 
assessed by fluorescence microscopy (panels b-d). A positive result by 
fluorescence microscopy is seen only in L6OCTN2GFP cells treated with the 
combination anti-OCTN2 and Cy3 sheep anti-rabbit Ig (panel c). B: Cells were 
detached with 10 mM EDTA, fixed with 2% paraformaldehyde for 20 minutes, 
washed and incubated first with anti-OCTN2 antiserum (anti-OCTN2/K33, 1/200 
dilution) and then with fluorescent labelled Cy3 sheep anti-rabbit Ig. 2x104 cells 
were used for analytical cell sorting on a FACSCalibur analyzer (Becton-
Dickinson). There is a clear shift of the signal in L6OCTN2GFP cells compared to 
L6GFP cells. 
 
Figure 4 
Functional characterization of the L6 cells overexpressing hOCTN2. The 
functionality of hOCTN2 was determined by L-[3H]-carnitine uptake experiments 
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as described in Methods. A: time dependency of sodium-dependent L-carnitine 
transport. While no sodium-dependent transport of L-carnitine can be detected in 
non-transfected L6 cells or L6 cells transfected with GFP, L6 cells transfected 
with hOCTN2/GFP have a high sodium-dependent transport activity which is 
linear up to at least 8 minutes. B: Assessment of the kinetics of L-carnitine 
transport into L6OCTN2GFP cells revealed saturable sodium-dependent 
transport of L-carnitine after correction for the sodium-independent component. 
The calculated Km and Vmax values for L-[3H]-carnitine transport are 9.7±0.3 μM 
and 290±4 pmol/mg protein/min, respectively. 
 
Figure 5. 
Inhibition of hOCTN2-driven transport of L-carnitine by verapamil. In order the 
investigate the interaction between hOCTN2 and verapamil in more detail, L-
carnitine transport by L6 cells overexpressing hOCTN2 was studied at several 
verapamil concentrations (A) and the IC50 was determined (B). L-carnitine 
transport was determined as described in Methods and incubations containing 
excess L-carnitine were used as controls. Verapamil turned out to be a potent 
inhibitor L-carnitine transport with an IC50 of 5.3 μmol/L. 
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Table 1 
Inhibition of hOCTN2 by substances carrying an ammonium ion and a carboxylic 
acid group. Inhibition was scored as follows: -, >80% hOCTN2 activity in the 
presence of 100 or 1000 μM potential inhibitor; +, <80% and >50% hOCTN2 
activity in the presence of 1000 μM inhibitor; ++, <50% hOCTN2 activity in the 
presence of 1000 μM inhibitor; +++, <50% hOCTN2 activity in the presence of 
100 μM inhibitor. 
 
Substance Carnitine 
transport (% 
of control, 
inhibitor 100 
μM) 
Carnitine 
transport (% 
of control, 
inhibitor 
1000 μM) 
Number of 
atoms 
between 
pharmaco-
phores 
Efficacy 
of 
inhibitor 
L-carnitine 49±4 15 3 +++ 
Acetylcarnitine 78±2 23±1 3 ++ 
Pivaloylcarnitine 91±1 56±4 3 + 
Hexanoylcarnitine 59±1 13±0 3 ++ 
Octanoylcarnitine 63±3 18±1 3 ++ 
Valproylcarnitine 96±8 77±3 3 + 
Palmitoylcarnitine 80±5 20±? 3 ++ 
Trimethylhydrazonium-
propionate 
92±0 34±2 3 ++ 
Butyrobetaine 57±3 16±1 3 ++ 
Dimethylaminobutyric acid 102±1 94±2 3 - 
Betaine 112±1 106±4 1 - 
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Table 2 
Inhibition of hOCTN2 by substances carrying an ammonium ion and a carboxylic 
acid group or a derivative thereof. Substances were selected and tested for 
hOCTN2 inhibition as described in Methods. Inhibition was scored as described 
in Table 1. 
 
Substance Carnitine 
transport 
(% of 
control, 
inhibitor 
100 μM) 
Carnitine 
transport 
(% of 
control, 
inhibitor 
1000 μM) 
Functional 
group closest to 
ammonium 
nitrogen 
(distance in 
atoms) 
Efficacy 
of 
inhibitor 
Atropine methylbromide 67±4 24±4 Inverted Ester 
(3) 
++ 
Anisotropine methyl 
bromide 
93±11 47±9 Inverted Ester 
(3) 
++ 
Ipratropium bromide 38±2 29±2 Inverted Ester 
(3) 
++ 
Scopolamine methyl 
bromide 
75±12 20±3 Inverted Ester 
(3) 
++ 
Scopolamine N-butyl 
bromide 
103±6 102±5 Inverted Ester 
(3) 
- 
Pancuronium bromide 93±2 59±2 Inverted Ester 
(2) 
+ 
Acetylcholine 85±5 83±3 Inverted Ester 
(2) 
- 
Carbamylcholine chloride 102±1 94±2 Inverted Ester 
(2) 
- 
Decamethonium bromide 88±3 91±9 none - 
Neostigmine bromide 91±4 85±11 Carbamate (3) - 
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Table 3 
Inhibition of hOCTN2 by substances carrying a constant positive charge on a 
nitrogen in an aromate. Substances were selected and tested for hOCTN2 
inhibition as described in Methods. Inhibition was scored as described in Table 1. 
 
Substance Carnitine 
Transport 
(% of 
control, 
inhibitor 
100 μM) 
Carnitine 
transport 
(% of 
control, 
inhibitor 
1000 μM) 
Number of 
atoms 
between 
pharmaco-
phores) 
Efficacy 
of 
inhibitor 
Ceftazidime 81±3 89±7 Carboxylate(
3) 
- 
Cefozoprane 94±9 78±2 Carboxylate 
(5) 
+ 
Amproilum hydrochloride 82±5 83±1 Amine (3) - 
Hexadecylpyridinium bromide 72±8 n.a.1 none n.a. 
Pyridostigmine bromide 92±6 92±4 Ester (2) - 
 
1n.a.: not assessable
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Table 4 
Inhibition of hOCTN2 by substances comprising either a cephalosporine or 
penicillin scaffold and the structural outlier verapamil. Substances were selected 
and tested for hOCTN2 inhibition as described in Methods. Inhibition was scored 
as described in Table 1. 
 
Substance Carnitine 
transport (% of 
control, 
inhibitor 100 
μM) 
Carnitine 
transport (% of 
control, 
inhibitor 1000 
μM) 
Efficacy of 
inhibitor 
Cefalotin 110±5 122±2 - 
Cefoxitin 80±22 87±3 - 
Ceftriaxone 84±9 83±5 - 
Cefazolin 100±7 91±11 - 
Cefamandole 90±6 96±2 - 
Cefuroxime 97±8 84±5 - 
Cephaloxin 91±8 82±13 - 
Ampicillin 82±6 90±2 - 
 
Verapamil 54±1 28±1 ++ 
 





